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What Is the “Mandatory” Duration?*Roxana Mehran, MD, Gennaro Giustino, MD, Usman Baber, MDSEE PAGE 1092T he worldwide implantation of intracoronarydrug-eluting stents (DES) continues to in-crease, with more than 5 million such inter-
ventions expected by 2018. Despite widespread use,
the optimal duration of dual antiplatelet therapy
(DAPT), deﬁned as the combination of a platelet
P2Y12 inhibitor and aspirin, remains unclear. The
need for antiplatelet therapy post-DES implantation
is predicated on mitigating risk for thrombotic
events, which is highest in the ﬁrst weeks to months
after percutaneous coronary intervention (PCI). Not
surprisingly, early cessation of DAPT has emerged as
a strong, consistent, and independent risk factor for
stent thrombosis (ST) (1,2). The potential for a sys-
temic beneﬁt of DAPT that extends beyond the local
stented segment to the remaining coronary vascula-
ture, coupled with concerns for late ST with early
generation DES, provide a pathobiological rationale
for longer (>1 year) DAPT durations. The unavoidable
corollary to extending the duration of antiplatelet
therapy is increased bleeding, a complication that
may have a more durable impact on long-term risk
than recurrent thrombosis (3). Indeed, bleeding con-
cerns—in concert with the improved biocompatibility
and clinical safety of second-generation DES—have
led to clinical equipoise on the optimal DAPT*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
From The Zena and Michael A. Wiener Cardiovascular Institute, Icahn
School of Medicine at Mount Sinai, New York, New York. Dr. Mehran is a
consultant for AstraZeneca, Bayer, CSL Behring, Janssen Pharmaceuticals
Inc., Merck & Co. Inc., Osprey Medical Inc., Regado Biosciences Inc., The
Medicines Company, Watermark Consulting; and is on the scientiﬁc
advisory board of Abbott Laboratories, AstraZeneca, Boston Scientiﬁc
Corporation, Covidien, Janssen Pharmaceuticals Inc., Merck & Co. Inc.,
The Medicines Company, and Sanoﬁ. Drs. Giustino and Baber have re-
ported that they have no relationships relevant to the contents of this
paper to disclose.duration after PCI on the basis of multiple random-
ized comparisons. To date, 7 randomized controlled
trials (RCTs) (Figure 1) have reported similar is-
chemic outcomes with 3- or 6-month DAPT duration
compared with longer DAPT regimens following DES
implantation. Conversely, with the exception of the
DAPT study, 2 RCTs failed to demonstrate a reduction
in ischemic events with DAPT prolongation beyond
12 months (4–17).It is within this context that Palmerini et al. (18)
report their ﬁndings from a patient-level pooled
analysis of 4 randomized trials (n ¼ 8,180) comparing
shorter (3- or 6-month) versus longer (12-month)
DAPT durations after DES PCI in this issue of the
Journal (18). Reﬂecting contemporary PCI practice
patterns, the most prevalent DES platforms in
the pooled cohort were everolimus-eluting and
zotarolimus-eluting stents, respectively. The authors
found nonsigniﬁcant differences in major adverse
cardiac events (MACE), deﬁned as the composite of
cardiac death, myocardial infarction, and deﬁnite/
probable ST, between groups at 12 months (hazard
ratio: 1.11; 95% conﬁdence interval: 0.86 to 1.43;
p ¼ 0.44). A shorter DAPT duration, however, yielded
signiﬁcant reductions in bleeding (hazard ratio: 0.66;
95% conﬁdence interval: 0.46 to 0.94; p ¼ 0.03).
Findings were concordant in several clinically re-
levant subgroups (sex, age, diabetes, clinical pre-
sentation, multivessel disease, and left anterior
descending artery as a target vessel) without evi-
dence of statistical interaction for the primary MACE
endpoint.
In addition to the primary patient-level analysis,
in which point estimates were stratiﬁed by trial,
the authors also performed indirect comparisons be-
tween DAPT durations across trials using a network
approach. Findings from these analyses were largely
FIGURE 1 DAPT Duration in Trials
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REAL-LATE/
ZEST–LATE [2011]4
12 Vs. 33 Months
PRODIGY [2012]5
6 Vs. 24 Months
EXCELLENT [2012]6
6 Vs. 12 Months
RESET [2013]7
3 Vs. 12 Months
OPTIMIZE [2014]8
3 Vs. 12 Months
ARCTIC-Interruption
[2014]9
12 Vs. 18–30 Months
SECURITY [2014]10
6 Vs. 12 Months
ITALIC [2014]11
6 Vs. 12 Months
ISAR–SAFE [2014]12
6 Vs. 12 Months
DAPT [2014]17
12 Vs. 30 Months
Meta–analysis / Pooled Analysis
•     No differences in MACE between shorter (median
       6.2 Months) and longer (median 16.8 months) DAPT
•      Shorter DAPT associated with less bleeding
Evidence
•      No differences in MACE between shorter
       (3 or 6 Months) and longer (≥ 12 Months) DAPT.
•       Shorter DAPT associated with less bleeding
•       No differences in MACE and bleeding between
        3 or 6 months DAPT
•      No differences in MACE and major bleeding between
       6 and 12 months of DAPT 
Cassese et al13
Meta–analysis
Palmerini et al18
Pooled Analysis
Stefanini et al14
Meta–analysis
Pandit et al15
Meta–analysis
EI–Hayek et al16
Meta–analysis
Bulluck et al20
Network Meta–analysis
•       Lower rates of MACE, ST and MI with longer DAPT
•       Lower rates of major bleeding with shorter DAPT
•       Higher all-cause mortality with longer DAPT?
Available evidence on DAPT duration is summarized from randomized controlled trials and meta-analyses. ARCTIC ¼ Double Randomization
of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus
Continuation of Double Antiplatelet Therapy; DAPT ¼ dual antiplatelet therapy; EXCELLENT ¼ Comparison of the Efﬁcacy of Everolimus-
Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions; ISAR-SAFE ¼ Safety and Efﬁcacy of Six Months Dual Antiplatelet Therapy
After Drug-Eluting Stenting; ITALIC ¼ Is There A LIfe for DES After Discontinuation of Clopidogrel; MACE ¼ major adverse cardiac event(s);
MI ¼ myocardial infarction; OPTIMIZE ¼ Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor Zotarolimus-
Eluting Stent in the Real World Clinical Practice; PRODIGY ¼ PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease
After Graded Stent-induced Intimal Hyperplasia study; REAL-LATE ¼ Correlation of Clopidogrel Therapy Discontinuation in Real World Patients
Treated with Drug-Eluting Stent Implantation and Late Coronary Arterial Thrombotic Events; RESET ¼ Real Safety and Efﬁcacy of a 3-month
Dual Antiplatelet Therapy Following Zotarolimus-eluting Stents Implantation; SECURITY ¼ Second-Generation Drug-Eluting Stent Implantation
Followed by 6- Versus 12-Month Dual Antiplatelet Therapy; ST ¼ stent thrombosis; ZEST-LATE ¼ Evaluation of the Long-Term Safety after
Zotarolimus-Eluting Stent, Sirolimus-Eluting Stent, or Paclitaxel-Eluting Stent Implantation for Coronary Lesions and Late Coronary Arterial
Thrombotic Events.
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1104concordant with the primary results, showing a safety
advantage with shorter DAPT duration without any
incremental thrombotic risk due to earlier cessation.
The investigators concluded that in a contemporary
practice with second-generation DES, a DAPT strategy
of 3 or 6 months is acceptable in selected patients
who are not at high risk for ischemic events.
Among the present analysis’ strengths is the in-
clusion of patient-level data, thereby allowing valid
inferences in key subgroups and multivariable ad-
justment within a propensity framework. Second, asmost participants in the pooled cohort were taking
DAPT for several months post-PCI irrespective of
randomized treatment assignment, the authors re-
peated all analyses in a landmark interval bounded
by time of DAPT discontinuation and 1 year. This
period, when groups are most different vis-à-vis
DAPT status, allows for more valid attribution of
events to the correct DAPT group and is of greatest
clinical interest. Findings from this “as-treated”
analysis were consistent with the primary intention-
to-treat approach. Third, most patients were treated
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1105with second-generation DES, enhancing generaliz-
ability to current PCI practice. These strengths
notwithstanding, the greatest limitation (readily
acknowledged by the authors) is the low rate of
ischemic adverse events accrued in each of the
respective randomized trials. As a result, and despite
pooling these data, power remained low to detect
modest, albeit clinically meaningful, differences in
these endpoints.
These results must be interpreted within the
context of the recently completed, large DAPT trial
(17). In contrast to the present analysis and earlier
studies, results from this trial demonstrated a sub-
stantial advantage with prolonged (30-month) versus
standard (12-month) DAPT duration in reducing
thrombotic events. The apparent discrepancies in
ﬁndings from these trials may be attributable to
several factors. First, the inclusion of more than
9,000 patients in the DAPT trial provided sufﬁcient
power to detect differences in low-frequency events,
including ST. Second, the assignment to a shorter- or
longer-duration group has been inconsistent across
trials, rendering comparisons of different DAPT stra-
tegies across studies difﬁcult. Indeed, the long-DAPT
group in the present analysis was deﬁned as 1 year;
this was the DAPT trial’s control arm. It is plausible
that the beneﬁts of continuing DAPT beyond the
initial high-risk period, when the need for potent
platelet inhibition is greatest, are realized in a time-
dependent fashion after sufﬁcient exposure to such
therapy. Analogously, the beneﬁts of statins are ap-
parent several weeks after exposure in high-risk ACS
patients, whereas up to 1 year or longer is required for
the beneﬁts to be apparent in more stable patients
with ischemic heart disease (19). Third, the beneﬁts
of extending DAPT may vary by important patient
and/or procedural parameters. In the DAPT trial,
for example, absolute risk reductions in MACE with
prolonged DAPT were 3.5% and 0.5% in patients
treated with ﬁrst- and second-generation stents, res-
pectively, translating into a number needed to treat
z29 and z200 for each respective stent platform. In
the current study, however, only z15% of patients
received ﬁrst-generation stents versusz38% of DAPT
study participants. In contrast to the variable results
across studies with respect to thrombotic beneﬁts, a
consistent and reproducible ﬁnding has been the
higher risk in bleeding complications with DAPT
prolongation. For example, the relative reduction
in bleeding with short DAPT in the present analysis
was 0.66, comparable to those observed in the
DAPT trial between groups. Moreover, in the DAPT
trial, the bleeding risk was uniform across
stent generations (number needed to harm z111 withboth ﬁrst- and second-generation DES). The uniform
bleeding risk across stent platforms and the higher
thrombotic risk with ﬁrst-generation DES highlight
the variability in risk/beneﬁt assessment as a func-
tion of stent type.
Interestingly, an updated study-level direct and
adjusted indirect meta-analysis on DAPT duration
has been published (20), with very similar results to
those of the present study. In the evidence hierarchy
of scientiﬁc research, the study of Palmerini et al.
(18) gives us the opportunity to move from study-
level to patient-level data. Individual patient-level
meta-analysis overcomes the limitations of study-
level meta-analysis, improving internal validity and
allowing for time-to-event, subgroup, and covariate-
adjusted analyses, or even generating risk score
models. Therefore, the present patient-level analysis
validates the results of previous meta-analyses, con-
ﬁrming that short-term DAPT appears safe in terms
of thrombotic events, whereas extended DAPT, even
for a relatively brief period, is associated with an
increased hazard of bleeding.
How, then, might clinicians assimilate the avail-
able and somewhat contradictory evidence to date to
inform routine decision making? Early after PCI, the
salient question centers on the minimum duration of
DAPT required to prevent largely local (i.e., stent-
related) complications. After this initial period, how-
ever, identifying those patients who might beneﬁt
most from DAPT extension to prevent increasingly
systemic thrombotic events becomes the key. The
existing evidence, including the present analysis,
suggests that 3 to 6 months of DAPT post-PCI may
sufﬁce for the former. Answering the latter, however,
requires a careful appraisal of a patient’s inherent
risk for recurrent thrombosis and bleeding and the
relative weight of each event on subsequent mortal-
ity. With respect to late ST, risk algorithms identify
various patient- and procedural-level parameters
that correlate with this complication. Analogous data
to identify patients at greatest risk for late bleeding,
however, remain unclear. This issue is clinically
relevant, as late bleeding is strongly associated with
mortality post-PCI and, therefore, should not be
considered a nuisance complication of DAPT. Finally,
although both thrombotic and bleeding complications
increase risk after PCI, the relative magnitude of
each event may vary by time after PCI. In the
recently reported DESERT (Drug-Eluting Stent Event
Registry of Thrombosis) registry, for example, Waks-
man et al. (21) found that late deﬁnite ST was asso-
ciated with a 2.6% mortality rate at 1 year, which is
much lower than the risk estimates previously re-
ported for acute and subacute ST. The risk/beneﬁt
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1106calculation for DAPT after PCI, therefore, must also
incorporate time after PCI as a parameter with prog-
nostic relevance.
At this juncture, after multiple RCTs in more
than 30,000 patients examining different durations
of DAPT, the optimal duration of DAPT after DES
remains unclear. As more evidence accrues, the
answer to this complex question will not be a “one-
size-ﬁts-all” approach. We return to our “gut” feeling
and the art of medicine to make important decisions
regarding this critical issue. In the absence of
a deﬁnitive answer, we lack a ﬁrm “mandatory”
duration of DAPT after new-generation DES. This
“mandatory” period should be deﬁned as the min-
imum time after PCI during which cessation of
DAPT results in an unacceptably high risk forthrombotic events. Beyond this timeframe, the deci-
sion to continue or discontinue DAPT will be on the
basis of evaluating the trade-off between ischemic
and bleeding risk according to the patient’s clinical
proﬁle. Hopefully, the growing body of evidence on
this subject will reﬁne our ability to accurately esti-
mate the patient’s ongoing ischemic and bleeding risk
and will inﬂuence clinical decision making in optimal
DAPT regimen selection.
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